Dr Reddy’s Laboratories today said it has launched Aripiprazole tablets used to treat certain mental/mood disorders in the United States market.
The drug, a therapeutic equivalent generic version of Abilify (Aripiprazole) tablets, has been introduced in the world’s biggest pharma market after getting approval from the US Food and Drug Administration (USFDA), the city-based company said in a statement.
The tablets are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths. The Abilify brand and generic tablets had the US sales of approximately USD 3.1 billion for the 12 months ended in August 2016 according to IMS Health, it said.
Aripiprazole is used to treat certain mental/mood disorders such as bipolar disorder, schizophrenia, Tourette’s disorder, and irritability associated with autistic disorder.
Abilify is a registered trademark of Otsuka Pharmaceutical Company.